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myeloablative in all  cases. Overall survival, leukemia free sur-
vival (LFS) and relapse incidence (RI) at 3 years were 57±4%, 
49±4% and 45±3%, respectively. Only 4 patients (1.9%) had 
VOD (moderate-2, severe-2)  at median day 16 (range, 10-47). 
One of the patients died from VOD.  Non relapse mortality at 3 
years was low 6±1%. In multivariate analysis the only progno-
stic factor that was found to be signifi cant for OS, LFS, RI and 
NRM was age >50 vs <50 years with p-value of <0.001, <0.001, 
<0.006 and <0.001, respectively (47±5%, 38±5%, 52±5%, 
10±3% vs 68±5%, 76±4%, 32±5% and 0%, respectively). 
In summary, these results suggest, that similar to the allogeneic 
setting, VOD is a very uncommon event after AutoSCT using iv Bu 
in the conditioning regimen translating into a low NRM incidence.
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We compared TBI/Cy to I.V Bu/Cy conditioning prior to alloSCT 
from HLA matched unrelated donors in 169 adult pts with AML 
in Rel 1. 95 pts were given TBI/Cy and 74 Bu/Cy. Median age 
was 38 (18-62) and 42 (19-72) years in the TBI/Cy vs. Bu/Cy 
groups, respectively (P<0.005). FAB classifi cation, cytogenetic 
risk, time from diagnosis to alloSCT, donor gender and CMV 
serostatus did not differ between the groups. Median year of 
alloSCT was 2004 vs. 2007, respectively (P<0.001). ATG was 
used in 35% vs. 71% in the TBI/Cy and Bu/Cy groups, respec-
tively (P<0.0001). 80% and 78% of the TBI/Cy and Bu/Cy groups 
received PBSC grafts, while 22% and 20% received BM grafts, 
respectively (P=0.8). Median follow-up was 23 (range, 1-125) 
and 27 (1-120) months in the TBI/Cy and Bu/Cy groups, respec-
tively. Engraftment was similar, 17 (10-33) and 16 (6-31) days 
in the TBI/Cy and Bu/Cy groups, respectively (P=0.23). Simi-
larly, acute GVHD (≥Gr II) incidence did not differ between the 
2 groups: 33% vs. 37% for the TBI/Cy vs. Bu/Cy, respectively. 
Death before day 100 occurred in 38% vs. 25% with TBI/Cy vs. 
Bu/Cy, respectively (P=0.25).  2y  NRM was similar between the 
2 groups,  28±5% vs. 19±5%, respectively (P=0.2). 2y relapse 
rate  was 54±5% vs. 50±6%, respectively (P=0.56). Induction of 
remission post alloSCT was higher with Bu/Cy vs TBI/Cy, 72% 
vs 54% (P=0.02). 2y LFS was also higher with the Bu/Cy vs 
TBI/Cy, groups: 23 ± 6% vs. 18±4%, respectively (P=0.045). 
Similarly, 2y OS was signifi cantly higher with Bu/Cy vs. TBI/Cy 
37±6% vs. 21±5%, respectively (P=0.013). The main cause 
of death was disease relapse: 53% and 60%, with TBI/Cy vs. 
Bu/Cy, respectively (p=0.49). VOD and infection-related deaths 
did not differ between the groups. In multivariate analysis the 
interval from diagnosis to transplant (> vs < 16 months) was the 
most signifi cant prognostic factor for Rel, LFS and OS 25±8% 
vs 59±4% (p=0.004), 48±9% vs 17±3% (p=0.002) and 41±7% 
vs 20±4% (p=0.003), respectively. Age, cytogenetic risk groups 
and use of ATG were not signifi cant prognostic factors for sur-
vival. In all, this observational registry based study suggest that 
in AML pts in fi rst Rel undergoing unrelated transplantation post 
transplant iv Bu/Cy vs TBI/Cy incuced higher remission rate 
which results in better LFS and OS. This advantage in favor 
of the iv Bu/Cy regimen is also possibly due to a lower overall 
toxicity and improved capacity for salvage therapy.
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We investigated the impact of occurrence of GVHD on trans-
plantation outcomes in a large cohort of AML pts given allo-
geneic PBSC after RIC conditioning. Data from 1859 AML pts 
in fi rst (n=1439) or second (n=420) CR transplanted between 
2000 and 2009 following a RIC regimen at EBMT affi liated cen-
tres were analyzed. Pts were given PBSC from HLA-identical 
sibling (MRD, n=1208), or from HLA-matched unrelated donors 
(MUD, n=651). ATG was given in 269 (22%) MRD and in 267 
(41%) MUD recipients, respectively, while 151 (13%) MRD and 
165 (25%) MUD recipients received in-vivo T cell depletion with 
alemtuzumab. The impact of chronic GVHD (cGVHD) on out-
comes was assessed using time-dependent multivariate Cox 
models and in a landmark analysis at 18 months after transplant. 
The 3-y cumulative incidence of cGVHD was 47%. Fifty-three 
percent of patients with cGVHD had extensive cGVHD, while 
the remaining 47% had limited cGVHD. In multivariate analy-
ses, occurrence of grade II-IV aGVHD was associated with a 
lower risk of relapse (HR=0.8; P=0.04), a higher risk of chro-
nic (HR=2.2; P<0.001) and extensive chronic GVHD (HR=2.8; 
P<0.001), a higher risk of NRM (HR=2.4 P<0.001), a worsened 
LFS (HR=1.3; P=0.01), and a worsened OS (HR=1.5; P<0.001). 
In multivariate time-dependent analyses, occurrence of limited 
cGVHD was associated with a lower risk of relapse (HR=0.7; 
P=0.05), comparable NRM (HR=1.4; P=0.16), comparable LFS 
(HR=0.9; P=0.29) and better OS (HR=0.5; P<0.001), while 
occurrence of extensive cGVHD was associated with a lower risk 
of relapse (HR=0.6; P=0.01), higher NRM (HR=3.2; P<0.001), 
a trend for worsened LFS (HR=1.3; P=0.06) and comparable 
OS (HR=0.9; P=0.34). In a landmark analysis in patients who 
were leukemia-free at 18 months after transplantation (n=776), 
2-year relapse, NRM, LFS and OS were 16±2%, 2.5±1%, 
82±2%, and 89±2%, respectively, in patients without cGVHD 
before the landmark time-point, versus 9±1% (P=0.001), 8±1% 
(P<0.001), 83±2% (P=0.65), and 86±2% (P=0.38), respectively, 
in patients with cGVHD before the landmark time-point. In con-
clusion, in this cohort of AML patients transplanted in remis-
sion, occurrence of cGVHD was associated with a lower risk 
of relapse that translated to better OS in patients with limited 
cGVHD but not in those with extensive cGVHD who experien-
ced higher long term NRM. These results highlight the role of 
the GVT effect in RIC allo-SCT, but also the need for improving 
the prevention of severe cGVHD in pts receiving RIC allo-SCT.
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In vivo T cell depletion of the graft with anti-thymocyte globulin 
(ATG) or with alemtuzumab has been frequently used in the 
